// Script to change toggle default state //G Smith second script to show/hide Leadership sections

Clinical Studies

Our technology has been validated in study after study and we continue to pursue active research to further new formulation development and confirm benefits in disease indices where we can have a positive impact.

Commitment to Research

We have always committed ourselves to rigorous research and validation on every aspect of our novel delivery and propriety formulation development. The company has completed and published more than 30 peer-reviewed papers on various aspects of our R&D and secured 135 patents on our I.P. in the U.S. and internationally. The information below provides background on our completed research and clinical trials and our ongoing validation studies as we continue to deliver on our mission of bringing better solutions for CNS-based disease treatment.

NEO100-01 GBM TRIAL

In 2019 NeOnc completed the first part of its human clinical trial of intranasally delivered NEO100’s impact on progressive or recurrent grade IV Glioma. NeOnc is now recruiting candidates for its NEO100-2a clinical trial.

LEARN MORE >

NEO212 TUMOR TRIAL

In our research, NeOnc has demonstrated that NEO212  delivers more TMZ directly to the brain better than TMZ on its own. This study will build on those findings treating astrocytoma IDH-mutant, glioblastoma IDH-wildtype, or uncontrolled metastases. NeOnc is now recruiting candidates for its NEO212 clinical trial.

LEARN MORE >

NEO100-03 PEDIATRIC HIGH-GRADE GLIOMA STUDY

NeOnc has determined that NEO100 may have an impact on treating Pediatric High-Grade Gliomas ( pHGGS) and is moving forward on enrollment to both the CIRM and PNOC to begin validation studies. NeOnc is in the process of filing the IND.

LEARN MORE >

NEO100-02 Meningioma Study

NeOnc has begun its open-label Phase 2 study to evaluate NEO100 as a single agent for patients with residual, progressive, or recurrent high-grade meningiomas. NeOnc is now recruiting candidates for its NEO100-02 clinical trial.

LEARN MORE >

Additional Indices

NeOnc has identified several non-cancer-related CNS-disease models where its delivery technology and formulations may be able to have a beneficial impact.

LEARN MORE >
 

Crossing the Barrier

The biggest barrier to better efficacy of pharma-based treatment of CNS cancers is not simply the need for better drugs, but rather, it is finding a better way to get the therapeutic to where it needs to go without compromising the therapeutic’s ability to effect a cure. And the biggest barrier to getting the therapeutic to where it needs to be is an actual barrier, the Blood Brain Barrier (BBB). The BBB serves as a natural first-line defense for the brain that prevents large molecule agents like viruses and neurotoxins from entering the cerebral tissue and causing harm. That same barrier, also limits and prevents beneficial agents such as chemotherapeutics from passing into the brain to get to a tumor site.

NeOnc Technologies has found a potential solution to this problem and is working to change the game actively when it comes to pharma-based CNS disease treatment.